Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

(2017) Michael Fralick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

(2017) Bernard Zinman et al.   STROKE

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

(2017) Kåre I Birkeland et al.   Lancet Diabetes & Endocrinology

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

(2017) Kenneth W. Mahaffey et al.   CIRCULATION

Use of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists

(2016) David Z.I. Cherney et al.   CIRCULATION

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials

(2016) H. L. Tang et al.   DIABETES OBESITY & METABOLISM

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

(2016) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

(2016) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney

(2016) Biff F. Palmer et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

(2016) Christoph Wanner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

(2015) Anne L. Peters et al.   DIABETES CARE

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2015) Silvio E. Inzucchi et al.   DIABETOLOGIA

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis

(2015) Lana Pinto et al.   Diabetology & Metabolic Syndrome

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus

(2013) Harold E. Bays et al.   Obesity

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE